Merck & Co., Inc.
MRKHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeMerck & Co., Inc. operates as a healthcare company worldwide. The company carries a $358.41B market cap, placing it firmly in the mega-cap category. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$358.41B
Beta
0.22
P/E (TTM)
115.29
P/E (Fwd)
15.69
EPS (TTM)
$1.26
EPS (Fwd)
$9.26
ROE
7.0%
ROA
11.9%
Cash
$7.14B
Total Debt
$53.91B
Free CF
$15.17B
52W Change
65.1%
Annual Financials
Cash vs Debt
Where MRK stands vs its 150-day and 200-day moving averages
As of the September 16, 2026 close, MRK finished 17.04% above its 150-day moving average ($122.86) and 21.62% above its 200-day moving average ($118.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRK overbought or oversold?
At the September 16, 2026 close, MRK's RSI(14) was 24.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MRK has $7.14B in cash with $53.91B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $15.17B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 7.0% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.9% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $59.28B (2022) to $65.01B (2025).
With a beta below 0.7, Merck & Co., Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Merck & Co., Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Merck & Co., Inc. and its sector.